PA8.DE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Nov 2023 @ 12:36):

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide...

Stats
Today's Volume	5 275.00
Average Volume	18 739.00
Market Cap	2.71M
EPS	€0 ( 2024-04-21 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.130
ATR14	€0.380 (105.56%)

Volume Correlation

Long: -0.58 (weak negative)

Short: 0.13 (neutral)

Signal:(15.842) Neutral

Paion AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Paion AG Correlation - Currency/Commodity

-0.64
( weak negative )

-0.62
( weak negative )

0.61
( weak )

-0.55
( weak negative )

-0.31
( neutral )

0.11
( neutral )

Paion AG Financials

Annual	2022
Revenue:	€33.25M
Gross Profit:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2022
Revenue:	€33.25M
Gross Profit:	€31.29M (94.10 %)
EPS:	€-0.0812

FY	2021
Revenue:	€7.13M
Gross Profit:	€4.05M (56.83 %)
EPS:	€-0.310

FY	2020
Revenue:	€19.66M
Gross Profit:	€19.66M (100.00 %)
EPS:	€0.0295

Financial Reports:

No articles found.

Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.